151 related articles for article (PubMed ID: 28730909)
1. Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.
Kim JS; Ryu JS; Jeon SH; Kim HJ; Nam HS; Cho JH; Kwak SM; Lee HL
J Int Med Res; 2018 Jan; 46(1):533-537. PubMed ID: 28730909
[TBL] [Abstract][Full Text] [Related]
2. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Drpa G; Sreter KB; Manojlovic S; Kukulj S
Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
[TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Venugopalan A; Lee MJ; Niu G; Medina-Echeverz J; Tomita Y; Lizak MJ; Cultraro CM; Simpson RM; Chen X; Trepel JB; Guha U
Oncotarget; 2016 Aug; 7(34):54137-54156. PubMed ID: 27494838
[TBL] [Abstract][Full Text] [Related]
5. De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Carney BJ; Rangachari D; VanderLaan PA; Gowen K; Schrock AB; Ali SM; Costa DB
Lung Cancer; 2017 Dec; 114():108-110. PubMed ID: 28870636
[No Abstract] [Full Text] [Related]
6. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
7. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
8. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
9. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
[TBL] [Abstract][Full Text] [Related]
10. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Erdogan B; Kodaz H; Karabulut S; Cinkaya A; Tozkir H; Tanriverdi O; Cabuk D; Hacioglu MB; Turkmen E; Hacibekiroglu I; Uzunoglu S; Cicin I
Bosn J Basic Med Sci; 2016 Nov; 16(4):280-285. PubMed ID: 27371767
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Schremser K; Rogowski WH; Adler-Reichel S; Tufman AL; Huber RM; Stollenwerk B
Pharmacoeconomics; 2015 Nov; 33(11):1215-28. PubMed ID: 26081300
[TBL] [Abstract][Full Text] [Related]
13. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Masuda K; Tokito T; Azuma K; Yanagida E; Nakamura M; Naito Y; Matsuo N; Ishii H; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2018 Jun; 9(6):754-757. PubMed ID: 29675860
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
[TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
19. [Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].
Li X; Yang H; Xu H; Wang S; Gao H
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):52-6. PubMed ID: 26805738
[TBL] [Abstract][Full Text] [Related]
20. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Hellmann MD; Reva B; Yu H; Rusch VW; Rizvi NA; Kris MG; Arcila ME
J Thorac Oncol; 2014 Oct; 9(10):e73-4. PubMed ID: 25521405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
